Zacks Investment Research on MSN1d
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key InsightsThe most recent trading session ended with Gilead Sciences (GILD) standing at $105.87, reflecting a -1.53% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss ...
Gilead Sciences Inc. closed 8.11% short of its 52-week high of $119.96, which the company achieved on March 10th.
In a report released today, Asthika Goonewardene from Truist Financial maintained a Hold rating on Gilead Sciences (GILD – Research Report).
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90 ...
With cancer diagnoses and death rates in Michigan often higher than the national average, a new, patient-centered ...
Nvidia stock rises after the chip maker makes a number of product announcements at its annual AI GTC conference, and Tesla ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback